News

Tuesday, 26. October 2021 | Filed under Company News

MIKROGEN Expands Diagnostic Product Range with T-Track® SARS-CoV-2 Test for Assessing T-cell Mediated Immune Responses

Mikrogen GmbH, a company developing genetically manufactured in vitro diagnostics, today announced the expansion of its product portfolio with the introduction of its T-Track® SARS-CoV-2 test to determine T-cell mediated immune responses.

The new RT-qPCR-based T-Track® assays (T-Track® SARS-CoV-2) detect the mRNA expression of specific marker cytokines, which in addition to the reactivity of memory T-cells also detect the reactivity of in vivo activated effector T-cells, thereby achieving the highest possible sensitivity. The new technology can detect several cytokines simultaneously by PCR with comparative ease and therefore stands out from other available methods for determining T-cell activity.

Read more…

Wednesday, 20. October 2021 | Filed under Company News

Curexsys Appoints Christian Eckert as Chief Operating Officer

– Strengthened management team headed by Jörg Neermann as CEO

Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Eckert, PhD, as Chief Operating Officer. He joins Curexsys´ recently expanded management board which consists of Jörg Neermann, PhD, Chief Executive Officer, and the Company´s co-founder Jens Gruber, PhD, Chief Scientific Officer.

Read more…

Wednesday, 13. October 2021 | Filed under Company News

ImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

– Preclinical data highlighting mode-of-action of lead program iosH2

ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that the Company will present a scientific poster at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) which will be held November 10-14, 2021, in Washington, DC, USA.

Read more…